Search Result

Isoforms Recommended:	CDK4

Results for "

CDK4

" in MedChemExpress (MCE) Product Catalog:

By Targets:	CDK (238) 5-HT Receptor (1) AAK1 (3) Akt (3) AMPK (4) Androgen Receptor (3) Apoptosis (68) Atg8/LC3 (1) Aurora Kinase (4) Autophagy (11) Bcl-2 Family (6) Bcr-Abl (1) Biochemical Assay Reagents (1) BMX Kinase (1) c-Met/HGFR (1) c-Myc (4) CaMK (1) Carbonic Anhydrase (1) Casein Kinase (2) Caspase (7) COX (1) CXCR (3) Cyclin G-associated Kinase (GAK) (2) Cytochrome P450 (1) Deubiquitinase (1) Discoidin Domain Receptor (1) DNA/RNA Synthesis (4) Drug Intermediate (1) Drug Metabolite (4) DYRK (1) E1/E2/E3 Enzyme (5) E3 Ligase Ligand-Linker Conjugates (3) EGFR (3) Ephrin Receptor (1) Epigenetic Reader Domain (5) ERK (4) Estrogen Receptor/ERR (2) Ferroptosis (2) FGFR (2) FLT3 (5) Fungal (1) FXR (2) Glutathione Peroxidase (1) GSK-3 (9) HDAC (3) Histamine Receptor (1) Histone Acetyltransferase (1) Histone Demethylase (1) Histone Methyltransferase (1) HIV (3) HSP (7) Hsp-targeting Chimeras (1) IRAK (1) Isotope-Labeled Compounds (6) Itk (1) JAK (2) Ligands for E3 Ligase (1) Ligands for Target Protein for PROTAC (5) LIM Kinase (LIMK) (3) MAP4K (2) MAPKAPK2 (MK2) (1) MDM-2/p53 (2) MEK (2) MELK (1) Mitochondrial Metabolism (1) Mixed Lineage Kinase (2) MMP (2) Molecular Glues (4) NF-κB (3) NO Synthase (1) p38 MAPK (2) PAK (2) Parasite (1) PARP (4) PDGFR (1) Phosphatase (1) Phosphodiesterase (PDE) (1) PI3K (4) Pim (2) PINK1/Parkin (1) PKC (4) PPAR (1) PROTAC Linkers (1) PROTACs (21) PSMA (2) Raf (2) Reactive Oxygen Species (ROS) (5) Reference Standards (20) RIP kinase (3) Salt-inducible Kinase (SIK) (3) SARS-CoV (1) Ser/Thr Kinase (1) Ser/Thr Protease (1) SHP2 (1) Small Interfering RNA (siRNA) (4) SnRK (1) SOD (1) STAT (2) Survivin (1) Syk (2) TAM Receptor (1) Target Protein Ligand-Linker Conjugates (1) Telomerase (1) Thrombopoietin Receptor (2) Tie (1) ULK (4) VEGFR (2) Wee1 (2) Wnt (2) YAP (1)
By Research Areas:	Cancer (257) Cardiovascular Disease (5) Endocrinology (1) Infection (3) Inflammation/Immunology (15) Metabolic Disease (7) Neurological Disease (17)
Click Chemistry:	PROTAC Synthesis (1) Alkynes (2)
Oligonucleotides:	Rat Pre-designed siRNA Sets (2) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (4)

273

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

Targets Recommended: CDK

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-16297A

Abemaciclib 115+ Cited Publications LY2835219	CDK	Neurological Disease Cancer
Abemaciclib (LY2835219) is a selective and BBB-permeable *CDK4/6* inhibitor with IC₅₀ values of 2 nM and 10 nM for CDK4 and CDK6, respectively.

HY-10005

Flavopiridol 50+ Cited Publications HMR-1275; Alvocidib; L86-8275	CDK Autophagy HIV Apoptosis	Cancer
Flavopiridol (Alvocidib) is a broad spectrum and competitive inhibitor of *CDKs, inhibiting CDK1, CDK2, CDK4* with IC₅₀s of 30, 170, 100 nM, respectively.

HY-16297

Abemaciclib methanesulfonate 115+ Cited Publications LY2835219 methanesulfonate	CDK	Cancer
Abemaciclib methanesulfonate (LY2835219 methanesulfonate) is a selective and BBB-permeable *CDK4/6* inhibitor with IC₅₀s of 2 nM and 10 nM for CDK4 and CDK6, respectively .

HY-101467

Trilaciclib 1 Publications Verification G1T28	CDK	Cancer
Trilaciclib (G1T28) is an orally active *CDK4/6* inhibitor with IC₅₀ values of 1 nM and 4 nM for CDK4 and CDK6, respectively. . Trilaciclib can effectively inhibit tumor cell proliferation and reduce the hematological toxicity caused by chemotherapy. Trilaciclib attenuates apoptosis and myelosuppression induced by 5FU (HY-90006) chemotherapy .

HY-18629

SU9516 5 Publications Verification	CDK Autophagy Apoptosis	Cancer
SU9516 is a potent *CDK2* inhibitor, with an IC₅₀ of 22 nM, and also shows inhibitory effects on CDK1 and CDK4, with IC₅₀s of 40, 200 nM, respectively.

HY-163640

CDK4 degrader 1	Molecular Glues CDK	Cancer
CDK4 degrader 1 (ML 1–71) is a molecular glue degrader that targets CDK4 .

HY-136250

BSJ-03-204	PROTACs CDK	Cancer
BSJ-03-204 is a PROTAC connected by ligands for Cereblon and *CDK. BSJ-03-204 is a potent and selective Palbociclib-based CDK4/6* dual degrader (PROTAC), with IC₅₀s of 26.9 nM and 10.4 nM for CDK4/D1 and CDK6/D1, respectively. BSJ-03-204 does not induce IKZF1/3 degradation and has anti-cancer activity .

HY-138946

XY028-140 1 Publications Verification	CDK PROTACs	Cancer
XY028-140 is a PROTAC connected by ligands for Cereblon and *CDK. XY028-140 inhibits both CDK4/6 expression and CDK4*/6 activity in cancer cells .

HY-129180

XY028-133	PROTACs CDK	Cancer
XY028-133 (example 14) is a PROTAC-based *CDK4/6* degrader with anti-tumor activity, which consists of ligands for von Hippel-Lindau and *CDK* .

HY-112272

Lerociclib 2 Publications Verification G1T38	CDK	Cancer
Lerociclib (G1T38) is a potent and selective inhibitor of *CDK4/6, with IC₅₀s* of 1 nM, 2 nM for CDK4/CyclinD1 and CDK6/CyclinD3, respectively.

HY-15889

AMG 925 2 Publications Verification	FLT3 CDK	Cancer
AMG 925 is a potent, selective, and orally available *FLT3/CDK4* dual inhibitor with IC₅₀s of 2±1 nM and 3±1 nM, respectively.

HY-16297AR

Abemaciclib (Standard) LY2835219 (Standard)	Reference Standards CDK	Cancer
Abemaciclib (Standard) is the analytical standard of Abemaciclib. This product is intended for research and analytical applications. Abemaciclib (LY2835219) is a selective and BBB-permeable *CDK4/6* inhibitor with IC₅₀ values of 2 nM and 10 nM for CDK4 and CDK6, respectively.

HY-163786

*PROTAC CDK4/6 degrader 1*	PROTACs CDK Apoptosis	Cancer
PROTAC CDK4/6 degrader 1 is a CDK4/CDK6 PROTAC degrader, with DC₅₀ values of 10.5 nM and 2.5 nM, respectively. PROTAC CDK4/6 degrader 1 inhibits the proliferation of Jurkat cells (IC₅₀ = 0.18 μM), arrests the cell cycle at the G1 phase, and induces apoptosis. PROTAC CDK4/6 degrader 1 can be used for cancer research.

HY-112280

Crozbaciclib CDK4/6/1 Inhibitor	CDK	Cancer
Crozbaciclib (CDK4/6/1 Inhibitor) is a *CDK4/6* inhibitor with IC₅₀s of 3 and 1 nM, respectively.

HY-142076

CDK4/6-IN-15	CDK	Cancer
CDK4/6-IN-15 is an orally active and selective *CDK4/6* inhibitor. CDK4/6-IN-15 potently inhibits cancer cells growth. CDK4/6-IN-15 arrests cell cycle at G1 phase and suppresses retinoblastoma tumour suppressor protein (Rb) phosphorylation at S780 and E2 factor (E2F)-regulated gene expression .

HY-45661

Inixaciclib NUV-422	CDK	Neurological Disease Cancer
Inixaciclib (NUV-422) is a blood-brain barrier-penetrant inhibitor of *CDK2, CDK4* and *CDK6. Inixaciclib inhibits cancer cell growth. Inixaciclib induces anti-tumor activity in xenograft models of glioblastoma, CDK4/CDK6* inhibitor-resistant HR ⁺ HER2 ^- metastatic breast cancer, and anti-androgen-resistant prostate cancer. Inixaciclib can be used for the research of relapsed or metastatic castration-resistant prostate cancer .

HY-16297AS

Abemaciclib-d8 LY2835219-d₈	CDK	Cancer
Abemaciclib-d₈ is the deuterium labeled Abemaciclib. Abemaciclib (LY2835219) is a selective CDK4/6 inhibitor with IC50 values of 2 nM and 10 nM for CDK4 and CDK6, respectively.

HY-164129

CDK4-IN-3	CDK Apoptosis	Cancer
CDK4-IN-3 (Compound 389) is a potent irreversible cyclin-dependent kinase 4 (CDK4) inhibitor (IC₅₀=25 nM, >10-fold selective over *CDK6). CDK4-IN-3* arrests the cell cycle at G₁ phase, and induces tumor cell apoptosis. CDK4-IN-3 is promising for research of solid tumors such as breast and lung cancers .

HY-101467A

Trilaciclib hydrochloride 1 Publications Verification G1T28 hydrochloride	CDK	Cancer
Trilaciclib (G1T28) hydrochloride is an orally active *CDK4/6* inhibitor with IC₅₀ values of 1 nM and 4 nM for CDK4 and CDK6, respectively. Trilaciclib hydrochloride can effectively inhibit tumor cell proliferation and reduce the hematological toxicity caused by chemotherapy. Trilaciclib hydrochloride attenuates apoptosis and myelosuppression induced by 5FU (HY-90006) chemotherapy .

HY-136252

BSJ-04-132	PROTACs CDK	Cancer
BSJ-04-132 is a PROTAC connected by ligands for Cereblon and *CDK. BSJ-04-132 is a potent and selective Ribociclib-based CDK4* degrader (PROTAC), with IC₅₀s of 50.6 nM and 30 nM for CDK4/D1 and CDK6/D1, respectively. BSJ-04-132 does not induce CDK6 and IKZF1/3 degradation. BSJ-04-132 has anti-cancer activity .

HY-152263

*HEMTAC CDK4/6 degrader 1*	Hsp-targeting Chimeras CDK Apoptosis	Cancer
HEMTAC CDK4/6 degrader 1 is a PROTAC connected by ligands for HSP90 and *CDK4/6* with a K_d value of 35.7 μM. HEMTAC CDK4/6 degrader 1 induces CDK4/6 degradation in B16F10 melanoma cells. HEMTAC CDK4/6 degrader 1 arrests cell cycle at G0/G1 phase and induces apoptosis. HEMTAC CDK4/6 degrader 1 can be used in research of cancer . HEMTAC CDK4/6 degrader 1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-50767S

Palbociclib-d8 PD 0332991-d₈	Isotope-Labeled Compounds CDK	Cancer
Palbociclib-d₈ is a deuterium labeled Palbociclib. Palbociclib is a selective and orally active CDK4 and CDK6 inhibitor with IC₅₀s of 11 and 16 nM, respectively. Palbociclib has the potential for ER-positive and HER2-negative breast cancer research .

HY-136726

CGP-82996 CINK4	CDK	Cancer
GP-82996 (CINK4) is a pharmacological inhibitor of *CDK4/6. GP-82996 has IC₅₀s of 1.5, 5.6 and 25 μM for CDK4/cyclin* D1, CDK6/cyclin D1 and Cdk5/p35, respectively. GP-82996 induces the apoptosis of cancer cells U2OS. GP-82996 can be used in the research of cancer .

HY-114339

CDK4/6-IN-2	CDK	Cancer
CDK4/6-IN-2 is a potent *CDK4* and *CDK6* inhibitor extracted from patent US20180000819A1, Compound 1, has IC₅₀s of 2.7 and 16 nM for CDK4 and CDK6, respectively .

HY-144995

BSJ-02-162 CDK4/6-IN-11	PROTACs CDK	Cancer
CDK4/6-IN-11 is a potent PROTAC CDK4/6 degrader . CDK4/6-IN-11 consists of a thalidomide-based E3 ligase ligand (blue part) Thalidomide-NH-CH2-COOH (HY-131717), a target protein ligand (red part) Palbociclib (HY-50767), and a PROTAC linker (black part) Boc-NH-C4-Br (HY-W007803). E3 ligase ligand and linker can form Thalidomide-NH-amido-C4-Br (HY-170307).

HY-137449

Rintodestrant G1T48	Estrogen Receptor/ERR CDK	Cancer
Rintodestrant (G1T48) is an orally active, non-steroidal and selective estrogen receptor degrader. Rintodestrant (G1T48) is also a *CDK4/6* inhibitor .

HY-112272A

Lerociclib dihydrochloride 2 Publications Verification G1T38 dihydrochloride	CDK	Cancer
Lerociclib dihydrochloride (G1T38 dihydrochloride) is a potent and selective inhibitor of *CDK4/CDK6*, with IC₅₀s of 1 nM and 2 nM for *CDK4/CyclinD1* and *CDK6/CyclinD3*, respectively.

HY-129336

Abemaciclib metabolite M20 5 Publications Verification LSN3106726	CDK	Cancer
Abemaciclib metabolite M20 (LSN3106726), the active metabolite of Abemaciclib, is a selective *CDK4*/6 inhibitor for the treatment of cancer .

HY-146213

CDK4/6-IN-12	CDK	Cancer
CDK4/6-IN-12 is a potent cyclin-dependent kinase 4/6 (CDK4/6) inhibitor. CDK4/6-IN-12 has enzymatic inhibitory activity for CDK4 and CDK6 with IC₅₀ of 592.3 nM and 3090 nM, respectively. CDK4/6-IN-12 can be used for the research of cancer .

HY-15612

CDK4-IN-1	CDK	Cancer
CDK4 inhibitor is a novel and specific CDK4/Cyclin D1 inhibitor with an IC50 of 10 nM; 1500 and 500 fold than CDK1/Cyclin B (IC50>15 uM) and CDK2/Cyclin A (IC50=5.265 uM) respectively.

HY-P1109

[Ala92]-p16 (84-103)	CDK	Cancer
[Ala92]-p16 (84-103) is a peptide derived from the p16CDKN2/INK4a (p16) tumor suppressor protein. [Ala92]-p16 (84-103) binds to both *cdk4* and *cdk6* and inhibits cdk4-cyclin D1 kinase activity in vitro (IC₅₀: 1.5 μM). [Ala92]-p16 (84-103) blocks cell cycle progression through the G1 phase .

HY-151898

CDK4/6-IN-14	CDK	Cancer
CDK4/6-IN-14 is a potent and highly selective *CDK4* and *CDK6* (CDK) inhibitor with IC₅₀s of 10 nM and 16 nM, respectively. CDK4/6-IN-14 exhibits more than 60-fold selectivity over CDKs 1, 2, 7, and 9, and shows high selectivity among other 205 kinases .

HY-136250A

BSJ-03-204 triTFA	PROTACs CDK	Cancer
BSJ-03-204 triTFA is a PROTAC connected by ligands for Cereblon and *CDK. BSJ-03-204 triTFA is a potent and selective Palbociclib-based CDK4/6* dual degrader (PROTAC), with IC₅₀s of 26.9 nM and 10.4 nM for CDK4/D1 and CDK6/D1, respectively. BSJ-03-204 triTFA does not induce IKZF1/3 degradation and has anti-cancer activity .

HY-153088

CDK4/6-IN-16	CDK	Cancer
CDK4/6-IN-16 (example 195) is a potent *CDK4* and *CDK6* inhibitor, with an IC₅₀ of 0.013 μM for *CDK4. CDK4/6-IN-16 can be used for the research of CDK4-mediated* disorders, such as cancer .

HY-115992

CDK4/6-IN-9	CDK	Cancer
CDK4/6-IN-9 (compound 10) is a selective *CDK4/6* inhibitor with an IC₅₀ of 905 nM for CDK6/cyclin D1. CDK4/6-IN-9 has the potential for multiple myeloma (MM) research .

HY-142076A

CDK4/6-IN-15 hydrochloride	CDK	Cancer
CDK4/6-IN-15 hydrochloride is an orally active and selective *CDK4/6* inhibitor. CDK4/6-IN-15 hydrochloride potently inhibits cancer cells growth. CDK4/6-IN-15 hydrochloride arrests cell cycle at G1 phase and suppresses retinoblastoma tumour suppressor protein (Rb) phosphorylation at S780 and E2 factor (E2F)-regulated gene expression .

HY-76558

Ethyl 4-chloro-2-(methylthio)pyrimidine-5-carboxylate	Biochemical Assay Reagents Drug Intermediate	Others
Ethyl 4-chloro-2-(methylthio)pyrimidine-5-carboxylate is a drug intermediate. Ethyl 4-chloro-2-(methylthio)pyrimidine-5-carboxylate can be used to synthesize inhibitors of various kinases such as Cdk4, PDGF, FGF, EGF .

HY-112243A

Cimpuciclib tosylate	CDK	Inflammation/Immunology Cancer
Cimpuciclib tosylate is a selective *CDK4* inhibitor (IC₅₀: 0.49 nM) that has anti-tumor activity .

HY-108907

SR-1277	Casein Kinase	Cancer
SR-1277 is a potent, selective and ATP competitive CK1δ/ε inhibitor, with IC₅₀s of 49 nM and 260 nM, respectively. SR-1277 also inhibits FLT3, CDK4/cyclin D1, CDK6/cyclin D3 and CDK9/cyclin K, with IC₅₀s of 305 nM, 1340 nM, 311 nM and 109 nM, respectively. SR-1277 can be used for the research of cancer .

HY-148213

CDK2/4/6-IN-1	CDK	Cancer
CDK2/4/6-IN-1(example 29) is a *CDK2/4/6* inhibitor with IC₅₀ values of 2.5, 23.7 and 44.3 nM for CDK2, CDK4 and CDK6, respectively. CDK2/4/6-IN-1 can be used in cancer research . CDK2/4/6-IN-1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-153336

PRT3645	CDK	Cancer
PRT3645 (Example 20) is a CDK Inhibitor. CDK-IN-12 Inhibits CDK4/6 with IC₅₀ values less than 20 nM .

HY-146214

CDK4/6-IN-13	CDK	Cancer
As a cdk4/6 inhibitor. Compounds 10B and 10C showed low nanomolar activity, ideal antiproliferative activity, excellent metabolic properties and acceptable pharmacokinetics on cdk4/6.

HY-178452

*PROTAC CDK4/6/9 degrader 1*	PROTACs CDK Apoptosis	Cancer
PROTAC CDK4/6/9 degrader 1 is a *CDK4/6/9* PROTAC degrader. PROTAC CDK4/6/9 degrader 1 degrades *CDK4, CDK6, and CDK9* in TNBC cells and inhibits TNBC cell proliferation. PROTAC CDK4/6/9 degrader 1 induces G1 phase arrest, promotes apoptosis, and suppresses cell migration and invasion in TNBC cells. PROTAC CDK4/6/9 degrader 1 can be used for the study of triple-negative breast cancer (TNBC). (Pink: CDK4/6/9 ligand (HY-168440), Blue: CRBN Ligand (HY-14658), Black: Linker (HY-178512), E3 ligase ligand-linker conjugate (HY-178515)) .

HY-178516

*PROTAC CDK4/6/9 degrader 2*	CDK PROTACs	Cancer
PROTAC CDK4/6/9 degrader 2 (Compound P4) is a CDK4/6/9 PROTAC prodrug with oral activity and low toxicity. PROTAC CDK4/6/9 degrader 2 can significantly inhibit tumor growth and suppress tumor lung metastasis. PROTAC CDK4/6/9 degrader 2 can be used in the research of cancer such as breast cancer. (Pink: CDK4/6/9 Ligand (HY-168440); Blue: CRBN Ligand (HY-178517); Black: Linker (HY-178512))

HY-134303

CST651 PROTAC CDK4/6 degrader 34	PROTACs CDK	Cancer
CST651 (PROTAC CDK4/6 degrader 34) is a selective *cyclin dependent kinase CDK4/6 PROTAC* degrader. CST651 can degrade CDK4 and CDK6 in MM.1S cells with DC₅₀ values of 20 and 5.1 nM. CST651 can inhibit cancer cells proliferation and migration. CST651 can be used for the research of cancer, such as acute lymphoblastic leukemia . (Structure Note: Pink: CDK4/6 ligand (HY-50767); Blue: VHL ligand (HY-125905); Black: linker (HY-W017440))

HY-103380

NSC 625987 1 Publications Verification	CDK	Cancer
NSC 625987 is a specific and high-affinity *CDK4* inhibitor with an IC₅₀ of 0.2 μM for CDK4:cyclin D1. NSC 625987 shows >500-fold selectivity for CDK4 over CDK2 .

HY-156646

Tibremciclib	CDK	Cancer
Tibremciclib is a CDK4 inhibitor with antineoplastic activity .

HY-16297R

Abemaciclib methanesulfonate (Standard) LY2835219 methanesulfonate (Standard)	Reference Standards CDK	Cancer
Abemaciclib (methanesulfonate) (Standard) is the analytical standard of Abemaciclib (methanesulfonate). This product is intended for research and analytical applications. Abemaciclib methanesulfonate (LY2835219 methanesulfonate) is a selective CDK4/6 inhibitor with IC50s of 2 nM and 10 nM for CDK4 and CDK6, respectively .

HY-175187

LO-3-63	CDK E1/E2/E3 Enzyme	Cancer
LO-3-63, a Ribociclib (HY-15777) analog bearing a truncated fumaramide handle, is a PROTAC-like *CDK4/6* degrader. LO-3-63 induces CUL4 ^DCAF16-dependent degradation of *CDK4/6* in cells .

HY-RS02382

Cdk4 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA) CDK	Others
Cdk4 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cdk4 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cdk4 Mouse Pre-designed siRNA Set A Cdk4 Mouse Pre-designed siRNA Set A

Cat. No.	Product Name	Target	Research Area

HY-P1109

[Ala92]-p16 (84-103)	CDK	Cancer
[Ala92]-p16 (84-103) is a peptide derived from the p16CDKN2/INK4a (p16) tumor suppressor protein. [Ala92]-p16 (84-103) binds to both *cdk4* and *cdk6* and inhibits cdk4-cyclin D1 kinase activity in vitro (IC₅₀: 1.5 μM). [Ala92]-p16 (84-103) blocks cell cycle progression through the G1 phase .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-18981

Decursin 2 Publications Verification (+)-Decursin	Classification of Application Fields Coumarins Phenylpropanoids Umbelliferae Plants Inflammation/Immunology Disease Research Fields Echinacea angustifolia DC. Source Classification	PKC Apoptosis CXCR
Decursin ((+)-Decursin) is a potent anti-tumor agent. Decursin also is a cytotoxic agent and a potent protein kinase C activator. Decursin induces apoptosis and cell cycle arrest at G1 phase. Decursin decreases the expression of CDK2, CDK4, CDK6, cyclin D1 protein at 48 h. Decursin inhibits cell proliferation and migration. Decursin shows anti-tumor, anti-inflammatory and analgesic activities ^[4].

HY-116035

Nimbolide 2 Publications Verification	Triterpenes Classification of Application Fields Terpenoids Azadirachta indica A. Juss. Plants Meliaceae Disease Research Fields Source Classification Cancer	Wnt NF-κB CDK Apoptosis
Nimbolide is a triterpene compound that can be isolated from neem (Azadirachta indica), possesses anticancer and antiproliferative activity. Nimbolide induces tumor cell apoptosis by inhibiting NF-κB and *CDK4/CDK6* kinase. Nimbolide suppresses the Wnt, PI3K-Akt, MAPK and JAK-STAT signaling pathways .

HY-N0805

Alisol B 23-acetate 3 Publications Verification 23-Acetylalismol B; 23-O-Acetylalisol B; Alisol B monoacetate	Triterpenes Alisma plantago-aquatica Linn. Classification of Application Fields Terpenoids Other Diseases Alismataceae Plants Disease Research Fields Source Classification	Apoptosis Reactive Oxygen Species (ROS) CDK MMP PARP FXR Syk
Alisol B 23-acetate is an orally active prototerpane-type triterpenoid. Alisol B 23-acetate can be isolated from Alisma orientalis. Alisol B 23-acetate induces Apoptosis, promotes ROS generation, downregulates *CDK4/6, MMP-2/9, upregulates cleaved PARP, activates FXR* and inhibits Syk. Alisol B 23-acetate has anti-inflammatory and hepatoprotective activities. Alisol B 23-acetate protects the kidney from ischemia-reperfusion injury. Alisol B 23-acetate has anticancer activity against ovarian cancer, colon cancer, lung cancer, and gastric cancer. Alisol B 23-acetate can be used in the study of atherosclerosis and allergic asthma ^[4] .

HY-103382

Arcyriaflavin A	Infection Alkaloids Structural Classification Microorganisms Classification of Application Fields Marine natural products Disease Research Fields Indole Alkaloids Source Classification	Fungal
Arcyriaflavin A is an indolo[2,3-a]carbazole compound and also a cyclin D1/CDK4 inhibitor. Arcyriaflavin A exists in the marine ascidian Eudistoma sp. and the slime mold Arcyria denudata. Arcyriaflavin A is applicable to research related to colon cancer and lung cancer .

HY-N7045

Isosilybin B 2 Publications Verification	Flavanonols Flavonoids Glycine soya Classification of Application Fields Phenols Polyphenols Cyamopsis tetragonoloba (L.) Taub. Plants Compositae Disease Research Fields Source Classification Cancer	Androgen Receptor Apoptosis CDK Caspase PSMA
Isosilybin B is a flavonolignan. Isosilybin B can be isolated from Silybum marianum. Isosilybin B can regulate cell cycle-related proteins (e.g., reduce cyclins (D3, D1, A, E), *Cdk4, Cdk2, Cdc25A), and activate Caspases* (Caspase-9 and Caspase-3). Isosilybin B can promote Apoptosis, reduce androgen receptor (AR) and PSA. Isosilybin B has anticancer activity against prostate cancer .

HY-N2887

Araliadiol	Natural Products Classification of Application Fields Aralia cordata Thunb. Plants Disease Research Fields Araliaceae Source Classification Cancer	Others
Araliadiol is a polyacetylenic compound isolated from the leaves of Aralia cordata Thunb. Araliadiol inhibits MCF-7 cells growth with an IC₅₀ value of 6.41 μg/mL .

HY-N3634

Corylifol C	Leguminosae Phenols Polyphenols Psoralea corylifolia L. Plants Source Classification	EGFR TAM Receptor Tie
Corylifol C is a potent protein kinase inhibitor with IC₅₀ valueS of 8.7, 3.0, 2.1, 6.4, 4.5, 6.2, 2.3, 1.2, 5.1 μg/ml for ARK5, Aurora-A, Aurora-B, AXL, B-RAF-VE, CDK4/CycD1, TIE2, EGF-R, EPHB4, respectively .

HY-116035R

Nimbolide (Standard)	Triterpenes Structural Classification Terpenoids Azadirachta indica A. Juss. Plants Meliaceae Source Classification	Wnt NF-κB CDK Apoptosis Reference Standards
Nimbolide (Standard) is the analytical standard of Nimbolide. This product is intended for research and analytical applications. Nimbolide is a triterpene compound that can be isolated from neem (Azadirachta indica), possesses anticancer and antiproliferative activity. Nimbolide induces tumor cell apoptosis by inhibiting NF-κB and CDK4/CDK6 kinase. Nimbolide suppresses the Wnt, PI3K-Akt, MAPK and JAK-STAT signaling pathways .

HY-18981R

Decursin (Standard) (+)-Decursin (Standard)	Structural Classification Coumarins Phenylpropanoids Umbelliferae Plants Echinacea angustifolia DC. Source Classification	Reference Standards PKC Apoptosis CXCR
Decursin (Standard) is the analytical standard of Decursin. This product is intended for research and analytical applications. Decursin ((+)-Decursin) is a potent anti-tumor agent. Decursin also is a cytotoxic agent and a potent protein kinase C activator. Decursin induces apoptosis and cell cycle arrest at G1 phase. Decursin decreases the expression of CDK2, CDK4, CDK6, cyclin D1 protein at 48 h. Decursin inhibits cell proliferation and migration. Decursin shows anti-tumor, anti-inflammatory and analgesic activities ^[3][4].

HY-N7045R

Isosilybin B (Standard)	Flavanonols Structural Classification Flavonoids Glycine soya Phenols Polyphenols Cyamopsis tetragonoloba (L.) Taub. Plants Compositae Source Classification	Reference Standards Androgen Receptor Apoptosis CDK Caspase PSMA
Isosilybin B (Standard) is the analytical standard of Isosilybin B (HY-N7045). This product is intended for research and analytical applications. Isosilybin B is a flavonolignan. Isosilybin B can be isolated from Silybum marianum. Isosilybin B can regulate cell cycle-related proteins (e.g., reduce cyclins (D3, D1, A, E), *Cdk4, Cdk2, Cdc25A), and activate Caspases* (Caspase-9 and Caspase-3). Isosilybin B can promote Apoptosis, reduce androgen receptor (AR) and PSA. Isosilybin B has anticancer activity against prostate cancer .

HY-N0805R

Alisol B 23-acetate (Standard) 23-Acetylalismol B (Standard); 23-O-Acetylalisol B (Standard); Alisol B monoacetate (Standard)	Triterpenes Structural Classification Alisma plantago-aquatica Linn. Terpenoids Alismataceae Plants Source Classification	Reference Standards Apoptosis Reactive Oxygen Species (ROS) CDK MMP PARP FXR Syk
Alisol B 23-acetate (Standard) is the analytical standard of Alisol B 23-acetate (HY-N0805). This product is intended for research and analytical applications. Alisol B 23-acetate is an orally active prototerpane-type triterpenoid. Alisol B 23-acetate can be isolated from Alisma orientalis. Alisol B 23-acetate induces Apoptosis, promotes ROS generation, downregulates *CDK4/6, MMP-2/9, upregulates cleaved PARP, activates FXR* and inhibits Syk. Alisol B 23-acetate has anti-inflammatory and hepatoprotective activities. Alisol B 23-acetate protects the kidney from ischemia-reperfusion injury. Alisol B 23-acetate has anticancer activity against ovarian cancer, colon cancer, lung cancer, and gastric cancer. Alisol B 23-acetate can be used in the study of atherosclerosis and allergic asthma ^[4] .

HY-N17617

S-Petasin	Structural Classification Natural Products Plants Petasites hybridus (L.) G.Gaertn., B.Mey. & Schreb. Compositae Source Classification	Phosphodiesterase (PDE) Apoptosis NO Synthase Caspase PPAR Bcl-2 Family PARP
S-Petasin is a phosphodiesterase (PDE) inhibitor with IC₅₀ values of 25.5 μM and 17.5 μM for PDE3 and *PDE4, respectively. S-Petasin inhibits cholesterol side-chain cleavage enzyme, 11β-hydroxylase, PPAR-γ, and iNOS* induction at RNA and protein levels. S-Petasin induces apoptosis, activates caspases, cleaves PARP, modulates mitochondrial membrane permeability, and regulates BCL2/BAX, p53, Bcl-XL, MMP-2, MMP-9, p21, *CDK4, and cyclin D1* expression. S-Petasin reduces inflammatory cell accumulation, cytokine and IgE levels, and enhances serum IgG2a levels. S-Petasin relaxes isolated sensitized guinea pig trachealis and exhibits gastrointestinal anti-spasmodic activity. S-Petasin reduces tonsillitis severity and asthmatic attack frequency. S-Petasin can be used for the research of prostate cancer, obesity, melanoma, allergic asthma, asthma, and peritonitis ^[4] .

Recombinant Proteins Recommended:

Cyclin-Dependent Kinase 4 (CDK4)

Species:	Human (6)
Tag:	His (4) Tag Free (1) Avi (2) GST (3) Flag (3)
Source:	Sf9 insect cells (5) E. coli (1)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P702860

	CDK4 Protein, Human (sf9, His, Avi) CDK4; Cell division protein kinase 4; CMM3; PSK-J3	Human	Sf9 insect cells
	CDK4 protein, acting as a Ser/Thr kinase in the cyclin D-CDK4 complex, critically regulates the G(1)/S transition by phosphorylating and inhibiting RB family members. This activity, specifically hypophosphorylation of RB1 during early G(1) phase, releases E2F and promotes transcription of genes that drive G(1) progression. CDK4 Protein, Human (sf9, His, Avi) is the recombinant human-derived CDK4, expressed by Sf9 insect cells, with N-Avi, N-His labeled tag. The total length of CDK4 Protein, Human (sf9, His, Avi) is 303 a.a..

HY-P704003

	CDK4 Protein, Human (sf9, His, Flag, Avi) CDK4; Cell division protein kinase 4; CMM3; PSK-J3	Human	Sf9 insect cells
	CDK4 protein, acting as a Ser/Thr kinase in the cyclin D-CDK4 complex, critically regulates the G(1)/S transition by phosphorylating and inhibiting RB family members. This activity, specifically hypophosphorylation of RB1 during early G(1) phase, releases E2F and promotes transcription of genes that drive G(1) progression. CDK4 Protein, Human (sf9, His, Flag, Avi) is the recombinant human-derived CDK4 protein, expressed by Sf9 insect cells, with Avi and N-His and N-Flag labeled tag.

HY-P702684

	CDK4-CCND3 Protein, Human (Active, sf9, GST, His) CDK4; cyclin-dependent kinase 4; PSK J3; cell division protein kinase 4; CMM3; PSK-J3; MGC14458;	Human	Sf9 insect cells
	CDK4 protein, acting as a Ser/Thr kinase in the cyclin D-CDK4 complex, critically regulates the G(1)/S transition by phosphorylating and inhibiting RB family members. This activity, specifically hypophosphorylation of RB1 during early G(1) phase, releases E2F and promotes transcription of genes that drive G(1) progression. CDK4-CCND3 Protein, Human (sf9, GST, His) is the recombinant human-derived CDK4-CCND3, expressed by Sf9 insect cells, with N-His, N-GST labeled tag.

HY-P702682

	CDK4-CCND1 Protein, Human (Active, sf9, GST, Flag, His) 1 Publications Verification CDK4; cyclin-dependent kinase 4; PSK J3; cell division protein kinase 4; CMM3; PSK-J3; MGC14458;	Human	Sf9 insect cells
	CDK4 protein, acting as a Ser/Thr kinase in the cyclin D-CDK4 complex, critically regulates the G(1)/S transition by phosphorylating and inhibiting RB family members. This activity, specifically hypophosphorylation of RB1 during early G(1) phase, releases E2F and promotes transcription of genes that drive G(1) progression. CDK4-CCND1 Protein, Human (sf9, GST, Flag, His) is the recombinant human-derived CDK4-CCND1, expressed by Sf9 insect cells, with N-His, N-GST, N-Flag labeled tag.

HY-P702683

	CDK4-CCND2 Protein, Human (Active, sf9, GST, Flag, His) CDK4; cyclin-dependent kinase 4; PSK J3; cell division protein kinase 4; CMM3; PSK-J3; MGC14458;	Human	Sf9 insect cells
	CDK4 protein, acting as a Ser/Thr kinase in the cyclin D-CDK4 complex, critically regulates the G(1)/S transition by phosphorylating and inhibiting RB family members. This activity, specifically hypophosphorylation of RB1 during early G(1) phase, releases E2F and promotes transcription of genes that drive G(1) progression. CDK4-CCND2 Protein, Human (sf9, GST, Flag, His) is the recombinant human-derived CDK4-CCND2, expressed by Sf9 insect cells, with N-His, N-GST, N-Flag labeled tag.

HY-P72785

	CDKN2A Protein, Human Cyclin-dependent kinase inhibitor 2A; CDK4I; MTS-1; p16INK4A	Human	E. coli
	CDKN2A Protein, a potent negative regulator of cell proliferation, forms strong interactions with CDK4 and CDK6, hindering their association with cyclins D and retinoblastoma protein phosphorylation. Acting in a heterodimeric manner, predominantly with CDK6, CDKN2A inhibits cyclin D-CDK4 kinase activity and interacts with ISCO2, contributing to its cell cycle regulatory role. CDKN2A Protein, Human is the recombinant human-derived CDKN2A protein, expressed by E. coli , with tag free.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-16297AS

Abemaciclib-d8
Abemaciclib-d₈ is the deuterium labeled Abemaciclib. Abemaciclib (LY2835219) is a selective CDK4/6 inhibitor with IC50 values of 2 nM and 10 nM for CDK4 and CDK6, respectively.

HY-15777S

Ribociclib-d6
Ribociclib-d₆ (LEE011-d₆) is a deuterium labeled Ribociclib (HY-15777). Ribociclib is a highly specific CDK4/6 inhibitor with IC₅₀ values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex .

HY-50767S

Palbociclib-d8
Palbociclib-d₈ is a deuterium labeled Palbociclib. Palbociclib is a selective and orally active CDK4 and CDK6 inhibitor with IC₅₀s of 11 and 16 nM, respectively. Palbociclib has the potential for ER-positive and HER2-negative breast cancer research .

HY-15777AS

Ribociclib-d6 hydrochloride
Ribociclib-d₆ (LEE011-d₆) hydrochloride is a deuterium labeled Ribociclib. Ribociclib is a highly specific CDK4/6 inhibitor with IC₅₀ values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex .

HY-129336S

Abemaciclib metabolite M20-d8
Abemaciclib metabolite M20-d₈ is the deuterium labeled Abemaciclib metabolite M20. Abemaciclib metabolite M20 (LSN3106726), the active metabolite of Abemaciclib, is a selective CDK4/6 inhibitor .

HY-15777S1

Ribociclib-d8
Ribociclib-d₈ is the deuterium labeled Ribociclib . Ribociclib (LEE01) is a highly specific CDK4/6 inhibitor with IC₅₀ values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex .

HY-128669S

Abemaciclib metabolite M2-d6
Abemaciclib metabolite M2-d₆ is the deuterium labeled Abemaciclib metabolite M2. Abemaciclib metabolite M2 (LSN2839567) is a metabolite of Abemaciclib, acts as a potent CDK4 and CDK6 inhibitor, with IC₅₀s in the range of 1-3 nM. Anti-cancer activity .

HY-126534S

Abemaciclib metabolite M18-d8
Abemaciclib metabolite M18-d₈ is the deuterium labeled Abemaciclib metabolite M18. Abemaciclib metabolite M18 (LSN3106729), the metabolite of Abemaciclib (HY-16297A), is a CDK inhibitor with antitumor activity. Abemaciclib metabolite M18 and a CRBN ligand have been used to design PROTAC CDK4/6 degrader .

HY-W654305

Palbociclib-d4

Palbociclib-d₄ is deuterium labeled Palbociclib. Palbociclib (PD 0332991) is an orally active selective CDK4 and CDK6 inhibitor with IC₅₀ values of 11 and 16 nM, respectively. Palbociclib has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma ^[4].

HY-50767S1

Palbociclib-d4 hydrochloride
Palbociclib-d₄ (hydrochloride) is the deuterium labeled Palbociclib hydrochloride. Palbociclib (PD 0332991) is a selective CDK4 and CDK6 inhibitor with IC₅₀s of 11 and 16 nM, respectively. Palbociclib has the potential for ER-positive and HER2-negative breast cancer research .

HY-176174S

CDK2-IN-46
CDK2-IN-46 (compound 5g) is a selective *CDK2* inhibitor with an IC₅₀ of 0.3 nM. CDK2-IN-46 has a selectivity of >200-fold for CDK1, CDK7, CDK9, CDK4, and CDK6. CDK2-IN-46 shows improves rat and cyno pharmacokinetic profiles .

HY-18981S

Decursin-d6

Decursin-d₆ ((+)-Decursin-d₆) is the deuterium labeled Decursin (HY-18981). Decursin ((+)-Decursin) is a potent anti-tumor agent. Decursin also is a cytotoxic agent and a potent protein kinase C activator. Decursin induces apoptosis and cell cycle arrest at G1 phase. Decursin decreases the expression of CDK2, CDK4, CDK6, cyclin D1 protein at 48 h. Decursin inhibits cell proliferation and migration. Decursin shows anti-tumor, anti-inflammatory and analgesic activities ^[4].

Host:	Mouse (10) Rabbit (6)
Reactivity:	Human (16) Rat (3) Mouse (8) Monkey (2)
Application:	IHC-P (12) ICC/IF (6) IP (5) WB (12) FC (8) ELISA (9)
Isotype:	IgG (6) IgG1 (6) IgG2a (2) IgG2b (1)
Conjugation:	Non-conjugated (16)
Clonality:	Monoclonal (11) Monoclonal Antibody (1) Recombinant (4)
Modification:	Unmodified (12)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P86471

	CDK4 Antibody (YA6163) CDK4; Cyclin-dependent kinase 4; Cell division protein kinase 4; PSK-J3	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	CDK4 Antibody (YA6163) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CDK4.

HY-P85531

	CDK4 Antibody (YA5223) CDK 4; CDK4; CDK4 protein; CDK4_HUMAN; Cell division kinase 4; Cell division protein kinase 4; CMM 3; CMM3; Crk3; Cyclin dependent kinase 4; Cyclin-dependent kinase 4; Melanoma cutaneous malignant 3; MGC14458; p34 CDK4; PSK J3; PSK-J3.	WB	Human, Mouse, Rat
	CDK4 Antibody (YA5223) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to CDK4.

HY-P80077

	Cdk4 Antibody (YA513) 2 Publications Verification	WB, ICC/IF, IHC-P, IP	Human, Mouse
	Cdk4 Antibody (YA513) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Cdk4.

HY-P84067

	CDK4 Antibody (YA3764) CMM3; PSK-J3	WB, IHC-P, FC, ELISA	Human, Mouse, Monkey
	CDK4 Antibody (YA3764) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to CDK4.

HY-P84066

	CDK4 Antibody (YA3763) CMM3; PSK-J3	IHC-P, ICC/IF, FC, ELISA	Human
	CDK4 Antibody (YA3763) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to CDK4.

HY-P84066A

	CDK4 Antibody (YA3763)(PBS only) CMM3; PSK-J3	IHC-P, ICC/IF, FC, ELISA	Human
	CDK4 Antibody (YA3763) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to CDK4.

HY-P84067A

	CDK4 Antibody (YA3764)(PBS only) CMM3; PSK-J3	WB, IHC-P, FC, ELISA	Human, Mouse, Monkey
	CDK4 Antibody (YA3764) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to CDK4.

HY-P80992

	CDKN2A/p16INK4a Antibody (YA3494) ARF antibody; CDK4 inhibitor p16 INK4 antibody; CDK4I antibody; CDKN2 antibody; CDKN2A antibody; Cell cycle negative regulator beta antibody; CMM2 antibody; INK4 antibody; INK4a antibody; Melanoma p16 inhibits CDK4 antibody; MLM antibody; MTS1 antibody; Multiple tumor suppressor 1 antibody; p16 antibody; p16 INK4a antibody; p16INK4a antibody; p19 antibody; P19ARF antibody; TP16 antibody;	WB, IHC-P	Human
	CDKN2A/p16INK4a Antibody (YA3494) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CDKN2A/p16INK4a.

HY-P80615

	CDKN2A/p16INK4a Antibody (YA508) 1 Publications Verification CDK4 inhibitor p16 INK4 antibody; CDK4I antibody; CDKN2 antibody; CDKN2A antibody; Cell cycle negative regulator beta antibody; CMM2 antibody; Cyclin dependent kinase 4 inhibitor A antibody; Cyclin dependent kinase inhibitor 2A (melanoma p16 inhibits CDK4) antibody; Cyclin Dependent Kinase Inhibitor 2A antibody; Cyclin dependent kinase inhibitor 2A isoform 4 antibody; Cyclin dependent kinase inhibitor 2A isoforms 1/2/3 antibody; Cyclin dependent kinase inhibitor p16 antibody; INK4 antibody; INK4A antibody; MLM antibody; MTS1 antibody; Multiple tumor suppressor 1 antibody; p14 antibody; p16 antibody; P16INK4 antibody; p16INK4a antibody; p19 antibody; p19Arf antibody; TP16 antibody;	WB, IP	Human, Mouse
	CDKN2A/p16INK4a Antibody (YA508) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CDKN2A/p16INK4a.

HY-P80615A

	CDKN2A/p16INK4a Antibody (YA508)(PBS only) CDK4 inhibitor p16 INK4 antibody; CDK4I antibody; CDKN2 antibody; CDKN2A antibody; Cell cycle negative regulator beta antibody; CMM2 antibody; Cyclin dependent kinase 4 inhibitor A antibody; Cyclin dependent kinase inhibitor 2A (melanoma p16 inhibits CDK4) antibody; Cyclin Dependent Kinase Inhibitor 2A antibody; Cyclin dependent kinase inhibitor 2A isoform 4 antibody; Cyclin dependent kinase inhibitor 2A isoforms 1/2/3 antibody; Cyclin dependent kinase inhibitor p16 antibody; INK4 antibody; INK4A antibody; MLM antibody; MTS1 antibody; Multiple tumor suppressor 1 antibody; p14 antibody; p16 antibody; P16INK4 antibody; p16INK4a antibody; p19 antibody; p19Arf antibody; TP16 antibody;	WB, IP	Human, Mouse
	CDKN2A/p16INK4a Antibody (YA508)(PBS only) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CDKN2A/p16INK4a.

HY-P88881

	CDKN2A/p14ARF Antibody (YA8565) ARF; CDK4I; CDKN2; CMM2; INK4; INK4A; MLM; MTS-1; MTS1; P14; P14ARF; P16; P16-INK4A; P16INK4	IHC-P, FC	Human
	CDKN2A/p14ARF Antibody (YA8565) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to CDKN2A/p14ARF.

HY-P88881A

	CDKN2A/p14ARF Antibody (YA8565)(PBS only) ARF; CDK4I; CDKN2; CMM2; INK4; INK4A; MLM; MTS-1; MTS1; P14; P14ARF; P16; P16-INK4A; P16INK4	IHC-P, FC	Human
	CDKN2A/p14ARF Antibody (YA8565) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to CDKN2A/p14ARF.

HY-P86438

	CDKN2A/p16INK4a Antibody (YA6130) 1 Publications Verification Cyclin-dependent kinase inhibitor 2A, isoforms 1/2/3; Cyclin-dependent kinase 4 inhibitor A; CDK4I; Multiple tumor suppressor 1; MTS-1; p16-INK4a; p16-INK4; p16INK4A; p16;	WB, ICC/IF, IP, ELISA	Human, Mouse, Rat
	CDKN2A/p16INK4a Antibody (YA6130) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CDKN2A/p16INK4a.

HY-P84321

	CDKN2A/p16INK4a Antibody (YA4018) ARF; MLM; P14; P16; P19; CMM2; INK4; MTS1; TP16; CDK4I; CDKN2; INK4A; MTS-1; P14ARF; P19ARF; P16INK4; P16INK4A; P16-INK4A	WB, IHC-P, FC, ELISA	Human
	CDKN2A/p16INK4a Antibody (YA4018) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to CDKN2A/p16INK4a.

HY-P85830

	CDKN2A/p16INK4a Antibody (YA5522) Cyclin-dependent kinase inhibitor 2A, isoforms 1/2/3; Cyclin-dependent kinase 4 inhibitor A; CDK4I; Multiple tumor suppressor 1; MTS-1; p16-INK4a; p16-INK4; p16INK4A; p16;	IHC-P, WB, ICC/IF, ELISA	Human
	CDKN2A/p16INK4a Antibody (YA5522) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to CDKN2A/p16INK4a.

HY-P84321A

	CDKN2A/p16INK4a Antibody (YA4018)(PBS only) ARF; MLM; P14; P16; P19; CMM2; INK4; MTS1; TP16; CDK4I; CDKN2; INK4A; MTS-1; P14ARF; P19ARF; P16INK4; P16INK4A; P16-INK4A	WB, IHC-P, FC, ELISA	Human
	CDKN2A/p16INK4a Antibody (YA4018) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to CDKN2A/p16INK4a.